SECsense Logo

Tiziana Life Sciences 6-K Report: New Collaboration with Renaissance for Foralumab Development

$TLSA
Form 6-K
Filed on: 2025-02-21
Source
Tiziana Life Sciences 6-K Report: New Collaboration with Renaissance for Foralumab Development

Here are the key insights extracted from the provided section of Tiziana Life Sciences LTD's 6-K report:

  1. Company Overview: The report pertains to Tiziana Life Sciences LTD, which is identified as a foreign private issuer.
  2. Filing Information:
  • Form Type: 6-K
  • Filing Date: February 21, 2025
  • Commission File Number: 001-38723
  1. Main Announcement:
  • Tiziana Life Sciences entered into a product development services agreement with Renaissance Lakewood LLC, a prominent Contract Development and Manufacturing Organization (CDMO) specializing in nasal drug delivery.
  • The objective of this collaboration is to optimize the formulation and develop a scale-up plan for foralumab, which is being developed for intranasal delivery targeting neurodegenerative and inflammatory conditions.
  1. Exhibit Details:
  • The report includes an attachment labeled as Exhibit 99.1, which contains a press release regarding the announcement of the collaboration.
  1. Legal Consideration:
  • The information provided in Exhibit 99.1 is furnished and is not considered "filed" under the Securities Exchange Act of 1934, meaning it does not carry the same legal liabilities as filed documents.
  1. Signatory Information:
  • The report is signed by Keeren Shah, the Chief Financial Officer of Tiziana Life Sciences LTD.
  1. Contact and Address:
  • The principal executive office is located at:
    • Tiziana Life Sciences LTD
    • 9th Floor, 107 Cheapside, London, EC2V 6DN.

This report reflects Tiziana's ongoing efforts in advancing their product pipeline, particularly with intranasal formulations, which may have significant implications for their business strategy and potential market impact in the pharmaceutical sector.